Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > November 6, 2020
Daily News
November 6, 2020
- MHLW Won’t Exclude Software Programs from Conditional Approval Coverage: Official
November 6, 2020
- University of the Ryukyus to Test Gout Drug Colchicine for COVID-19
November 6, 2020
- Bill to Amend Immunization Act to Enter Lower House Deliberations on November 10
November 6, 2020
- 1st Half Sales of 7 Major Japan Drug Makers Skid 1.9% on Price Cuts, COVID-19; Core Products Brisk
November 6, 2020
- Before Aducanumab AdCom, Eisai CEO Voices Hopes for Potential 1st Alzheimer’s Drug in 17 Years
November 6, 2020
- Package Insert Revisions Ordered for Opdivo, Copaxone
November 6, 2020
- Eisai Racks Up 5.9% Sales Increase in April-September on Lenvima Growth, Despite Price Cuts, COVID-19
November 6, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…